Blood pressure response, but not adverse event incidence, correlates with dose of angiotensin II antagonist

Journal of Hypertension, Supplement

Volumn 19, Issue 1, 2001, Pages

  Puchler K ^a   Laeis, P ^a   Stumpe, K O ^a  

^a Sankyo Europe GmbH   (Germany)

Author keywords

Angiotensin II antagonists; Hypertension; Meta analysis; Olmesartan medoxomil; Renin angiotensin aldosterone system

Indexed keywords

ANGIOTENSIN 1 RECEPTOR ANTAGONIST; OLMESARTAN; PLACEBO; UNCLASSIFIED DRUG;

ADULT; AGED; BLOOD PRESSURE REGULATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; ESSENTIAL HYPERTENSION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SIDE EFFECT; SYSTOLIC BLOOD PRESSURE;

EID: 0034951771     PISSN: 09521178     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004872-200106001-00006     Document Type: Review

References (18)

1. Implementation of WHO/ISH guidelines: Role and activities of WHO
2. Interrupting the renin-angiotensin system: The role of angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonists in the treatment of hypertension
3. AT1-receptor blockers in hypertension and heart failure: Clinical experience and future directions
4. 1999 World Health Organisation-International Society of Hypertension guidelines for the management of hypertension
5. Non-peptide angiotensin type I receptor antagonists in the treatment of hypertension
6. Comparative safety and tolerability of angiotensin II receptor antagonists
7. Angiotensin II receptor antagonists and hypertension
8. The sixth report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure
9. New drugs for the treatment of hypertension
10. Losartan, an orally active angiotensin (AT1) receptor antagonist: A review of its efficacy and safety in essential hypertension
11. Clinical overview of irbesartan: A new angiotensin II receptor antagonist
12. Valsartan. A review of its pharmacology and therapeutic use in essential hypertension
13. Telmisartan
14. Efficacy and tolerability of irbesartan, an angiotensin II receptor antagonist, in primary hypertension. A double-blind, placebo-controlled, dose-titration study
15. Optimal dosing characteristics of the angiotensin II receptor antagonist telmisartan
16. Irbesartan. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in the management of hypertension
17. 1 receptor antagonists
18. Angiotensin II receptor antagonists: Losartan, valsartan, irbesartan and candesartan